Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
- Industry News
- Technology
- Software
- Banking
- Automotive
- Energy
- More
- Drug Approvals
- Clinical Trial Calendar

Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard

Crypto
Cryptocurrency
Blockchain

Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies

Politics
US
World
White House
Elections
General News

Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard

Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health

Slide Shows

Entertainment
Top Stories
- Pop
- Rock
- Classic Rock
- Rap/Hip-Hop
- Country
- Alternative
- Oldies
- All Genre

Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services

Premium
Intelligent Investor
Biotech Investor NEW
Login

Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us

Business
Corp. News
- Latest Headlines
- Biotech
- Investors
- Stock Alerts
- IPOs
- M&A
Industry News
- Technology
- Software
- Banking
- Automotive
- Energy
- More
Corp. Calendars
Earnings Calendar
FDA Calendars
- Drug Approvals
- Clinical Trial Calendar
Ratings Changes
Economy
- US
- Europe
- Asia
- Global
- Economic Calendar
- Economic Scorecard
Crypto
- Cryptocurrency
- Blockchain
Markets
Market News
Politics
- US
- World
- White House
- Elections
- General News
Forex
Health
Health News
Slide Shows
Entertainment
Entertainment News
- Top Stories
Music News
- Pop
- Rock
- Classic Rock
- Rap/Hip-Hop
- Country
- Alternative
- Oldies
- All Genre
Content Licensing
Premium
More

Sanofi Sa (SAN.PA)

Teva: Blackstone Life Sciences To Provide $400 Mln To Support Development Of Duvakitug 3/4/2026 1:11:03 AM

Sanofi's Rilzabrutinib Gets Orphan Drug Designation In Japan For IgG4-Related Disease 3/2/2026 3:37:02 AM

Sanofi: Rilzabrutinib Granted Orphan Drug Designation In Japan For IgG4-related Disease 3/2/2026 1:34:23 AM

Sanofi’s Rilzabrutinib Secures Orphan Drug Designation In Japan For IgG4-Related Disease 3/2/2026 1:05:25 AM

Regeneron, Sanofi Receive Positive CHMP Opinion For Dupixent In Pediatric CSU 2/27/2026 7:42:09 AM

Regeneron And Sanofi Receive Positive CHMP Opinion For Dupixent In Treating Pediatric Chronic Spontaneous Urticaria 2/27/2026 7:05:02 AM

Sanofi's Acoziborole Receives Positive CHMP Opinion For Sleeping Sickness Treatment 2/27/2026 6:23:38 AM

Sanofi: EMA's CHMP Grants Positive Opinion To Acoziborole Winthrop For Gambiense Sleeping Sickness 2/27/2026 6:05:26 AM

FDA Approves Sanofi And Regeneron's Dupixent As First Medicine For Allergic Fungal Rhinosinusitis 2/25/2026 12:42:31 AM

Sanofi : FDA Approves Dupixent As First Treatment For Allergic Fungal Rhinosinusitis 2/24/2026 10:50:10 PM

Weekly Buzz: NRXP Sets The Path For NRX-100's NDA; IRON Gets FDA's CRL; TOVX Licenses SYN-020 2/20/2026 9:27:44 AM

Sanofi, Teva Report Positive Phase 2b Results For Duvakitug 2/17/2026 9:22:25 AM

Sanofi Appoints Manuela Buxo As Head Of Specialty Care, Effective March 1, 2026 2/17/2026 8:37:47 AM

Sanofi And Teva Announce Positive Results From RELIEVE UCCD Long-term Extension Study 2/17/2026 8:30:04 AM

Sanofi: Beyfortus Study Shows Benefit For Infants Beyond First RSV Season 2/16/2026 2:00:44 AM

Sanofi : Lancet Study Shows Beyfortus Provides Protection For Infants Beyond First RSV Season 2/16/2026 1:09:20 AM

Sanofi CEO Paul Hudson To Exit On Feb.17, 2026; Belén Garijo, CEO Of Merck KGaA, Named Successor 2/12/2026 3:09:37 AM

Sanofi CEO Paul Hudson To Depart; Belén Garijo Named Successor 2/12/2026 2:09:11 AM

Sanofi Appoints Belén Garijo As CEO To Succeed Paul Hudson In April 2026 2/12/2026 1:50:04 AM

Sanofi: Belén Garijo To Become CEO 2/12/2026 1:49:02 AM

- « Previous
- 1
- 2
- 3
Older Articles

Copyright © 2026 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service. About Us | Contact Us | Privacy | Sitemap